卵巢上皮性癌转录激活因子-2表达与顺铂耐药的关系

Study on the Relationship between the Expression of ATF-2 and Cisplatin Resistance in Ovarian Epithelial Carcinoma

目的:探讨卵巢上皮性癌组织转录激活因子-2(ATF-2)表达水平与顺铂耐药的关系。方法:应用免疫组化链霉素抗生物-过氧化物酶连接(SP)法检测56例石蜡包埋卵巢癌标本的ATF-2蛋白表达,逆转录聚合酶链反应(RT-PCR)方法检测其中34例卵巢癌新鲜组织的ATF-2 mRNA表达,分析其与顺铂耐药的关系。结果:不同年龄、组织学类型及有无腹水患者ATF-2表达差别无统计学意义,而不同手术分期患者表达差异有统计学意义(P<0.05)。顺铂化疗耐药组、敏感组ATF-2蛋白表达染色积分值分别为4.88±2.94、2.80±3.10,差异有统计学意义(t=2.568,P<0.05),RT-PCR结果显示34例卵巢上皮性癌新鲜组织中ATF-2/β-actin mRNA波动于0.181～2.276,化疗耐药者、敏感者ATF-2 mRNA相对表达量分别为1.132±0.645、0.651±0.461,差异有统计学意义(t=2.136,P<0.05)。结论:ATF-2表达与卵巢上皮性癌顺铂耐药有关,可能成为预测卵巢癌顺铂敏感性指标。

Objective： To investigate the relationship between the expression of activated transcription factor 2 （ATF-2 ） and cisplatin resistance in ovarian epithelial carcinoma. Methods： The expression of ATF-2 protein was examined in 56 ovarian cancer samples by streptavidin-peroxidase complex technique. The semi-quantitative reverse transcription polymerase chain reaction（RT-PCR） method was applied to assess the mRNA levels of ATF-2 genes in 34 fresh ovarian carcinoma tissues. The relationship was analyzed between the expression of ATF-2 and cisplatin resistance. Results： The expressions of ATF-2 did not show any significant difference in patient’s age, pathologic type and ascitic fluid. However, those were different among FIGO stage. The positive protein expressions of ATF-2 were 4.88±2.94 and 2.80±3.10 in chemoresistant group and chemosensitive group （t = 2.568, P 0.05）. RT-PCR results showed that the fluctuation of ATF-2/β-actin mRNA was 0.181 to 2.276. The expression level of ATF-2 mRNA were 1.132±0.645 and 0.651±0.461 in chemoresistant patients and chemosensitive patients （t = 2.136, P 0.05）. Conclusion： The expression of ATF-2 was related to cisplatin resistance in ovarian epithelial carcinoma, which may be valuable in predicting cisplatin response.